Skip to Content

Imbruvica (ibrutinib) Disease Interactions

There are 9 disease interactions with Imbruvica (ibrutinib):

Moderate

Ibrutinib (Includes Imbruvica) ↔ Atrial Fibrillation

Moderate Potential Hazard, Moderate plausibility

Applies to: Arrhythmias

Atrial fibrillation and atrial flutter have occurred in patients treated with ibrutinib. The risk is increased in patients with cardiac risk factors, hypertension, acute infections, and a previous history of atrial fibrillation. It is recommended to monitor patients clinically for atrial fibrillation periodically and those patients who develop arrhythmic symptoms (e.g., palpitations, lightheadedness) or new onset dyspnea should have an ECG performed. Atrial fibrillation should be managed appropriately, and if it persists to consider the risks and benefits of ibrutinib treatment and follow dose modification according to clinical guidelines.

Moderate

Ibrutinib (Includes Imbruvica) ↔ Bleeding

Moderate Potential Hazard, Moderate plausibility

Applies to: Bleeding Associated with Coagulation Defect

Cases of bleeding, including bruising, petechia, intracranial hemorrhage, including subdural hematoma; gastrointestinal bleeding, hematuria, post procedural hemorrhage, some leading to fatal bleeding events have been reported in patients treated with ibrutinib. Patients receiving antiplatelet or anticoagulant therapy may be at an increased risk of hemorrhage and these patients should be closely monitored for signs of bleeding. It is recommended to consider withholding ibrutinib for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

Moderate

Ibrutinib (Includes Imbruvica) ↔ Cytopenia

Moderate Potential Hazard, Moderate plausibility

Applies to: Bone Marrow Depression/Low Blood Counts

Cytopenias including neutropenia, thrombocytopenia, and anemia have been reported with use of ibrutinib. Care should be taken with patients at risk, and it is recommended to monitor for complete blood counts monthly or as clinically appropriate.

Moderate

Ibrutinib (Includes Imbruvica) ↔ Hepatic Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Ibrutinib is metabolized in the liver. In clinical trials, patients with hepatic impairment showed an increase in ibrutinib exposure following a single dose administration. It is recommended to monitor patients for signs of toxicity and follow dose modification as appropriate. The use of ibrutinib is not recommended in patients with moderate or severe hepatic impairment.

Moderate

Ibrutinib (Includes Imbruvica) ↔ Hypertension

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypertension

The use of ibrutinib may cause hypertension. It is recommended to monitor for new onset hypertension or hypertension that is not adequately controlled after starting therapy and to adjust hypertensive medications and/or initiate antihypertensive treatment per clinical practices. Close monitoring of blood pressure is recommended.

Moderate

Ibrutinib (Includes Imbruvica) ↔ Infections

Moderate Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Fatal and non-fatal infections, including cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP), have been reported with the use of ibrutinib. It is recommended to assess patients for fever and infections and treat appropriately.

Moderate

Ibrutinib (Includes Imbruvica) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The use of ibrutinib in patients with mild to moderate renal impairment is not expected to influence on the exposure to ibrutinib. Caution and close monitoring is recommended in patients with severe renal impairment or patients on dialysis as there are no data available for these patients.

Moderate

Ibrutinib (Includes Imbruvica) ↔ Tumor Lysis Syndrome

Moderate Potential Hazard, Moderate plausibility

Applies to: Tumor Lysis Syndrome

Tumor lysis syndrome has been reported with ibrutinib therapy. It is recommended to assess the baseline risk (e.g., high tumor burden) and take appropriate precautions. Monitor patients closely and treat as appropriate.

Moderate

Multikinase Inhibitors (Includes Imbruvica) ↔ Lung Toxicity

Moderate Potential Hazard, Moderate plausibility

Applies to: Interstitial Pneumonitis, Pulmonary Impairment

The use of certain multikinase inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, permanently discontinue these agents and institute appropriate measures. Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.

Imbruvica (ibrutinib) drug Interactions

There are 439 drug interactions with Imbruvica (ibrutinib)

Imbruvica (ibrutinib) alcohol/food Interactions

There are 2 alcohol/food interactions with Imbruvica (ibrutinib)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide